That's correct. The example Mr. Masterson gave also applies in some cases to pharmaceuticals and the treatment of excipients or other products that are incorporated in the products. If we do it here, we have to go through a rigorous pedigree and an audit, and the other side will probably not look to see if the other foreign companies are doing the same thing. That gives us a lot of costs and a disincentive to produce the products in Canada.
On February 7th, 2019. See this statement in context.